Matching articles for "fluticasone propionate"

Drugs for COPD

   
The Medical Letter on Drugs and Therapeutics • September 2, 2024;  (Issue 1710)
The main goals of treatment of chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, prevent disease progression, and reduce...
The main goals of treatment of chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, prevent disease progression, and reduce mortality. GOLD (Global Initiative for Chronic Obstructive Lung Disease) guidelines for treatment of COPD were updated recently. Treatment of acute exacerbations is not discussed here. Drugs available for treatment of COPD are listed in Tables 1 and 3.
Med Lett Drugs Ther. 2024 Sep 2;66(1710):137-44 | Show Full IntroductionHide Full Introduction

Comparison Table: Inhaled Drugs for Treatment of COPD (online only)

   
The Medical Letter on Drugs and Therapeutics • September 2, 2024;  (Issue 1710)
...
View the Comparison Table: Inhaled Drugs for Treatment of COPD
Med Lett Drugs Ther. 2024 Sep 2;66(1710):e143-7 | Show Full IntroductionHide Full Introduction

Olopatadine/Mometasone (Ryaltris) for Allergic Rhinitis

   
The Medical Letter on Drugs and Therapeutics • January 23, 2023;  (Issue 1668)
The FDA has approved Ryaltris (Hikma), a fixed-dose combination nasal spray containing the H1-antihistamine olopatadine hydrochloride (Patanase, and generics) and the corticosteroid mometasone furoate...
The FDA has approved Ryaltris (Hikma), a fixed-dose combination nasal spray containing the H1-antihistamine olopatadine hydrochloride (Patanase, and generics) and the corticosteroid mometasone furoate (Nasonex 24 HR Allergy, and generics), for treatment of seasonal allergic rhinitis symptoms in persons ≥12 years old. Ryaltris is the second intranasal antihistamine/corticosteroid combination to be approved for this indication; azelastine 0.1%/fluticasone propionate (Dymista, and generics), which is approved for use in persons ≥6 years old, was the first. Both products are available only by prescription.
Med Lett Drugs Ther. 2023 Jan 23;65(1668):12-4 | Show Full IntroductionHide Full Introduction

Drugs for Allergic Rhinitis and Allergic Conjunctivitis

   
The Medical Letter on Drugs and Therapeutics • April 19, 2021;  (Issue 1622)
The choice of drugs for treatment of allergic rhinitis depends on the severity of symptoms and whether they are intermittent or persistent (see Table...
The choice of drugs for treatment of allergic rhinitis depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).
Med Lett Drugs Ther. 2021 Apr 19;63(1622):57-64 | Show Full IntroductionHide Full Introduction

Comparison Table: Some Oral Drugs for Allergic Rhinitis (online only)

   
The Medical Letter on Drugs and Therapeutics • April 19, 2021;  (Issue 1622)
...
View the Comparison Table: Some Oral Drugs for Allergic Rhinitis
Med Lett Drugs Ther. 2021 Apr 19;63(1622):e63-5 | Show Full IntroductionHide Full Introduction

Comparison Table: Some Nasal Sprays for Allergic Rhinitis (online only)

   
The Medical Letter on Drugs and Therapeutics • April 19, 2021;  (Issue 1622)
...
View the Comparison Table: Some Nasal Sprays for Allergic Rhinitis
Med Lett Drugs Ther. 2021 Apr 19;63(1622):e66-71 | Show Full IntroductionHide Full Introduction

Drugs for Asthma

   
The Medical Letter on Drugs and Therapeutics • December 14, 2020;  (Issue 1613)
The goal of asthma treatment is to control symptoms, prevent exacerbations, and maintain normal lung function. Management of acute exacerbations of asthma in the emergency department is not discussed...
The goal of asthma treatment is to control symptoms, prevent exacerbations, and maintain normal lung function. Management of acute exacerbations of asthma in the emergency department is not discussed here.
Med Lett Drugs Ther. 2020 Dec 14;62(1613):193-200 | Show Full IntroductionHide Full Introduction

Table: Some Inhaled Drugs for Treatment of Asthma (online only)

   
The Medical Letter on Drugs and Therapeutics • December 14, 2020;  (Issue 1613)
...
View the table: Some Inhaled Drugs for Treatment of Asthma
Med Lett Drugs Ther. 2020 Dec 14;62(1613):e200-3 | Show Full IntroductionHide Full Introduction

Drugs for COPD

   
The Medical Letter on Drugs and Therapeutics • September 7, 2020;  (Issue 1606)
The main goals of treatment for chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, and prevent disease progression. Several...
The main goals of treatment for chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, and prevent disease progression. Several guidelines and review articles on COPD treatment have been published in recent years. Treatment of acute exacerbations is not discussed here.
Med Lett Drugs Ther. 2020 Sep 7;62(1606):137-44 | Show Full IntroductionHide Full Introduction

Comparison Table: Inhaled Long-Acting Bronchodilators for Treatment of COPD (online only)

   
The Medical Letter on Drugs and Therapeutics • September 7, 2020;  (Issue 1606)
...
View the Comparison Table: Inhaled Long-Acting Bronchodilators for Treatment of COPD
Med Lett Drugs Ther. 2020 Sep 7;62(1606):e146-7 | Show Full IntroductionHide Full Introduction

Comparison Table: Inhaled Corticosteroids for Treatment of COPD (online only)

   
The Medical Letter on Drugs and Therapeutics • September 7, 2020;  (Issue 1606)
...
View the Comparison Table: Inhaled Corticosteroids for Treatment of COPD
Med Lett Drugs Ther. 2020 Sep 7;62(1606):e148-9 | Show Full IntroductionHide Full Introduction

Table: Correct Use of Inhalers for COPD (online only)

   
The Medical Letter on Drugs and Therapeutics • September 7, 2020;  (Issue 1606)
...
View the Table: Correct Use of Inhalers for COPD
Med Lett Drugs Ther. 2020 Sep 7;62(1606):e150-4 | Show Full IntroductionHide Full Introduction

Drugs for Atopic Dermatitis

   
The Medical Letter on Drugs and Therapeutics • June 15, 2020;  (Issue 1600)
Atopic dermatitis (AD; also known as eczema) is frequently associated with other atopic disorders such as allergic rhinitis, asthma, and food allergy. It commonly presents in infancy and early childhood and...
Atopic dermatitis (AD; also known as eczema) is frequently associated with other atopic disorders such as allergic rhinitis, asthma, and food allergy. It commonly presents in infancy and early childhood and has a relapsing course, often improving by adolescence, but sometimes persisting into (or first appearing in) adulthood or even old age.
Med Lett Drugs Ther. 2020 Jun 15;62(1600):89-96 | Show Full IntroductionHide Full Introduction

OTC Drugs for Seasonal Allergies

   
The Medical Letter on Drugs and Therapeutics • April 22, 2019;  (Issue 1570)
Patients with seasonal allergies often experience nasal itching and congestion, sneezing, rhinorrhea, and itchy, watery eyes. Oral, intranasal, and ophthalmic preparations are widely available over the...
Patients with seasonal allergies often experience nasal itching and congestion, sneezing, rhinorrhea, and itchy, watery eyes. Oral, intranasal, and ophthalmic preparations are widely available over the counter (OTC) for relief of symptoms. Prescription products for management of allergic rhinitis and allergic conjunctivitis are reviewed separately.
Med Lett Drugs Ther. 2019 Apr 22;61(1570):57-60 | Show Full IntroductionHide Full Introduction

Trelegy Ellipta - A Three-Drug Inhaler for COPD

   
The Medical Letter on Drugs and Therapeutics • May 21, 2018;  (Issue 1547)
The FDA has approved Trelegy Ellipta (GSK), a fixed-dose combination of the inhaled corticosteroid (ICS) fluticasone furoate, the long-acting antimuscarinic agent (LAMA) umeclidinium, and the...
The FDA has approved Trelegy Ellipta (GSK), a fixed-dose combination of the inhaled corticosteroid (ICS) fluticasone furoate, the long-acting antimuscarinic agent (LAMA) umeclidinium, and the long-acting beta2-agonist (LABA) vilanterol. It is available as a dry powder inhaler for once-daily maintenance treatment of COPD and to reduce COPD exacerbations in patients with a history of exacerbations. Trelegy Ellipta is the first three-drug inhaler for treatment of COPD to become available in the US.
Med Lett Drugs Ther. 2018 May 21;60(1547):86-8 | Show Full IntroductionHide Full Introduction

Drugs for Asthma

   
The Medical Letter on Drugs and Therapeutics • August 28, 2017;  (Issue 1528)
The goal of asthma treatment is to control symptoms and prevent exacerbations. Management of acute exacerbations of asthma is not discussed...
The goal of asthma treatment is to control symptoms and prevent exacerbations. Management of acute exacerbations of asthma is not discussed here.
Med Lett Drugs Ther. 2017 Aug 28;59(1528):139-46 | Show Full IntroductionHide Full Introduction

Comparison Table: Some Inhaled Drugs for Treatment of Asthma (online only)

   
The Medical Letter on Drugs and Therapeutics • August 28, 2017;  (Issue 1528)
...
View the Comparison Table: Some Inhaled Drugs for Treatment of Asthma
Med Lett Drugs Ther. 2017 Aug 28;59(1528):e146-9 | Show Full IntroductionHide Full Introduction

Comparison Table: Correct Use of Inhalers for Asthma (online only)

   
The Medical Letter on Drugs and Therapeutics • August 28, 2017;  (Issue 1528)
...
View the Comparison Table: Correct Use of Inhalers
Med Lett Drugs Ther. 2017 Aug 28;59(1528):e150-2 | Show Full IntroductionHide Full Introduction

Comparison Table: Some Topical Corticosteroids (online only)

   
The Medical Letter on Drugs and Therapeutics • May 8, 2017;  (Issue 1520)
...
View the Comparison Table: Some Topical Corticosteroids
Med Lett Drugs Ther. 2017 May 8;59(1520):e91-5 | Show Full IntroductionHide Full Introduction

OTC Fluticasone Furoate Nasal Spray (Flonase Sensimist) for Allergic Rhinitis (online only)

   
The Medical Letter on Drugs and Therapeutics • April 24, 2017;  (Issue 1519)
The nasal spray formulation of the corticosteroid fluticasone furoate is now available over the counter (OTC) as Flonase Sensimist Allergy Relief (GSK) in the same strength as the prescription product...
The nasal spray formulation of the corticosteroid fluticasone furoate is now available over the counter (OTC) as Flonase Sensimist Allergy Relief (GSK) in the same strength as the prescription product (Veramyst) for treatment of seasonal or perennial allergic rhinitis. It is the fourth intranasal corticosteroid to become available OTC.
Med Lett Drugs Ther. 2017 Apr 24;59(1519):e70-1 | Show Full IntroductionHide Full Introduction

Drugs for COPD

   
The Medical Letter on Drugs and Therapeutics • April 10, 2017;  (Issue 1518)
The main goals of treatment for chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, and prevent disease progression. Updated...
The main goals of treatment for chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, and prevent disease progression. Updated guidelines for treatment of COPD have been published in recent years.
Med Lett Drugs Ther. 2017 Apr 10;59(1518):57-62 | Show Full IntroductionHide Full Introduction

Comparison Table: Inhaled Long-Acting Bronchodilators for COPD (online only)

   
The Medical Letter on Drugs and Therapeutics • April 10, 2017;  (Issue 1518)
...
View the Comparison Table: Inhaled Long-Acting Bronchodilators for COPD
Med Lett Drugs Ther. 2017 Apr 10;59(1518):e64-5 | Show Full IntroductionHide Full Introduction

Comparison Table: Some Inhaled Corticosteroids for COPD (online only)

   
The Medical Letter on Drugs and Therapeutics • April 10, 2017;  (Issue 1518)
...
View the Comparison Table: Some Inhaled Corticosteroids for COPD
Med Lett Drugs Ther. 2017 Apr 10;59(1518):e66 | Show Full IntroductionHide Full Introduction

Table: Correct Use of Inhalers for COPD (online only)

   
The Medical Letter on Drugs and Therapeutics • April 10, 2017;  (Issue 1518)
...
View the Table: Correct Use of Inhalers for COPD
Med Lett Drugs Ther. 2017 Apr 10;59(1518):e67-71 | Show Full IntroductionHide Full Introduction

Fluticasone Furoate (Arnuity Ellipta) for Asthma

   
The Medical Letter on Drugs and Therapeutics • May 25, 2015;  (Issue 1469)
The FDA has approved Arnuity Ellipta (GSK), a single-agent inhaler containing the corticosteroid fluticasone furoate, for once-daily maintenance treatment of asthma in patients ≥12 years old. Fluticasone...
The FDA has approved Arnuity Ellipta (GSK), a single-agent inhaler containing the corticosteroid fluticasone furoate, for once-daily maintenance treatment of asthma in patients ≥12 years old. Fluticasone furoate is also available in combination with the long-acting beta2-agonist vilanterol as Breo Ellipta for treatment of asthma and COPD.
Med Lett Drugs Ther. 2015 May 25;57(1469):76-9 | Show Full IntroductionHide Full Introduction

OTC Fluticasone Nasal Spray for Allergic Rhinitis

   
The Medical Letter on Drugs and Therapeutics • March 30, 2015;  (Issue 1465)
The nasal spray formulation of the corticosteroid fluticasone propionate is now available over the counter (OTC) as Flonase Allergy Relief (GSK) in the same strength as the prescription product (Flonase,...
The nasal spray formulation of the corticosteroid fluticasone propionate is now available over the counter (OTC) as Flonase Allergy Relief (GSK) in the same strength as the prescription product (Flonase, and generics) for patients ≥4 years old with seasonal or perennial allergic rhinitis. It is the second corticosteroid nasal spray to become available OTC; triamcinolone acetonide (Nasacort Allergy 24HR) was the first. Unlike prescription Flonase, the OTC product is FDA-approved for reduction of ocular as well as nasal symptoms. Brand-name prescription Flonase has been discontinued by the manufacturer.
Med Lett Drugs Ther. 2015 Mar 30;57(1465):48-9 | Show Full IntroductionHide Full Introduction

Olodaterol (Striverdi Respimat) for COPD

   
The Medical Letter on Drugs and Therapeutics • January 5, 2015;  (Issue 1459)
Olodaterol (Striverdi Respimat – Boehringer Ingelheim), a new inhaled long-acting beta2-agonist, has been approved by the FDA for once-daily maintenance treatment of airflow obstruction in patients...
Olodaterol (Striverdi Respimat – Boehringer Ingelheim), a new inhaled long-acting beta2-agonist, has been approved by the FDA for once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). It is not approved for treatment of acute exacerbations of COPD or for treatment of asthma. Olodaterol is the third long-acting beta2-agonist to be approved by the FDA for once-daily use; indacaterol (Arcapta Neohaler), which is available as a single agent, and vilanterol, which is available only in fixed-dose combinations with the long-acting anticholinergic umeclidinium (Anoro Ellipta) or the corticosteroid fluticasone furoate (Breo Ellipta), were approved earlier.
Med Lett Drugs Ther. 2015 Jan 5;57(1459):1-3 | Show Full IntroductionHide Full Introduction

Drugs for Allergic Disorders

   
The Medical Letter on Drugs and Therapeutics • May 1, 2013;  (Issue 129)
The use of drugs to prevent and control symptoms of allergic disorders can be optimized when patients avoid exposure to specific allergens and/or environmental conditions that trigger or worsen their...
The use of drugs to prevent and control symptoms of allergic disorders can be optimized when patients avoid exposure to specific allergens and/or environmental conditions that trigger or worsen their symptoms.
Treat Guidel Med Lett. 2013 May;11(129):43-52 | Show Full IntroductionHide Full Introduction

Azelastine/Fluticasone Propionate (Dymista) for Seasonal Allergic Rhinitis

   
The Medical Letter on Drugs and Therapeutics • October 29, 2012;  (Issue 1402)
The FDA has approved a nasal spray fixed-dose combination (Dymista – Meda) of the H1-antihistamine azelastine (Astelin, Astepro, and generics) and the corticosteroid fluticasone propionate (Flonase, and...
The FDA has approved a nasal spray fixed-dose combination (Dymista – Meda) of the H1-antihistamine azelastine (Astelin, Astepro, and generics) and the corticosteroid fluticasone propionate (Flonase, and generics) for treatment of seasonal allergic rhinitis (SAR) in patients ≥12 years old who need both medications for symptomatic relief. It is the first nasal spray to be approved in the US that contains both an H1-antihistamine and a corticosteroid.
Med Lett Drugs Ther. 2012 Oct 29;54(1402):85-7 | Show Full IntroductionHide Full Introduction

In Brief: Stopping Long-Acting Beta-2 Agonists

   
The Medical Letter on Drugs and Therapeutics • March 22, 2010;  (Issue 1334)
A little more than a year ago, The Medical Letter reported the results of an FDA meta-analysis which found that use of a long-acting beta-2 agonist (LABA) such as salmeterol (Severent) or formoterol (Foradil)...
A little more than a year ago, The Medical Letter reported the results of an FDA meta-analysis which found that use of a long-acting beta-2 agonist (LABA) such as salmeterol (Severent) or formoterol (Foradil) in patients with asthma was associated with an increased risk of a composite endpoint of asthma-related death, intubation or hospitalization; the highest risk was in children 4-11 years old.There was no significant increase in risk when a long-acting beta-2 agonist was used with an inhaled corticosteroid.The Medical Letter recommended that long-acting beta-2 agonists should not be used as monotherapy for asthma, especially in children, and that long-acting beta-2 agonists should be used for asthma only in combination with an inhaled corticosteroid, preferably in a fixed-dose combination in the same inhaler.1

Now the FDA has issued new Safe Use Requirements2 and labeling requirements for long-acting beta-2 agonists that include the following: “Stop use of the LABA, if possible, once asthma control is achieved and maintain the use of an asthma-controller medication such as an inhaled corticosteroid.”3

It has not been determined that patients taking a longacting beta-2 agonist in a fixed-dose combination with an inhaled corticosteroid have an increased risk of death or that stopping long-acting beta-2 agonists in such patients will improve long-term outcomes. A controlled clinical trial of these new requirements would be welcome.

1. Long-acting beta-2 agonists in asthma. Med Lett Drugs Ther 2009; 51:1.
2. www.fda.gov/safety/medwatch/default.htm
3. BA Chowdhury and G Dal Pan. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N Engl J Med 2010; Feb 24 (epub).

Download: U.S. English
Med Lett Drugs Ther. 2010 Mar 22;52(1334):21 | Show Full IntroductionHide Full Introduction

Drugs for Acne, Rosacea and Psoriasis

   
The Medical Letter on Drugs and Therapeutics • November 1, 2008;  (Issue 75)
The pathogenesis of acne is multifactorial: follicular hyperkeratinization, bacteria, sebum production, androgens and inflammation all play a role. The gram-positive microaerophilic bacteria Propionibacterium...
The pathogenesis of acne is multifactorial: follicular hyperkeratinization, bacteria, sebum production, androgens and inflammation all play a role. The gram-positive microaerophilic bacteria Propionibacterium acnes promote development of acne lesions by secreting chemotactic factors that attract leukocytes to the follicle, causing inflammation.
Treat Guidel Med Lett. 2008 Nov;6(75):75-82 | Show Full IntroductionHide Full Introduction

Ciclesonide (Alvesco) - A New Inhaled Corticosteroid for Asthma

   
The Medical Letter on Drugs and Therapeutics • September 22, 2008;  (Issue 1295)
The FDA has approved the marketing of the corticosteroid ciclesonide (Alvesco - Sepracor) in a hydrofluoroalkane (HFA) metered-dose inhaler formulation for maintenance treatment of asthma in patients >12 years...
The FDA has approved the marketing of the corticosteroid ciclesonide (Alvesco - Sepracor) in a hydrofluoroalkane (HFA) metered-dose inhaler formulation for maintenance treatment of asthma in patients >12 years old. Ciclesonide is also available in the US as a nasal spray for allergic rhinitis (Omnaris), and has been available for asthma in Europe since 2003.
Med Lett Drugs Ther. 2008 Sep 22;50(1295):75-6 | Show Full IntroductionHide Full Introduction

Ciclesonide (Omnaris) for Allergic Rhinitis

   
The Medical Letter on Drugs and Therapeutics • May 5, 2008;  (Issue 1285)
Ciclesonide (Omnaris - Sepracor/Nycomed), a once daily corticosteroid nasal spray, is now available for treatment of seasonal allergic rhinitis (SAR) in adults and children ≥6 years old and for perennial...
Ciclesonide (Omnaris - Sepracor/Nycomed), a once daily corticosteroid nasal spray, is now available for treatment of seasonal allergic rhinitis (SAR) in adults and children ≥6 years old and for perennial allergic rhinitis (PAR) in those ≥12 years old. An orally inhaled formulation of ciclesonide (Alvesco) was recently approved by the FDA for maintenance treatment of asthma, and will be reviewed in a future issue of The Medical Letter
Med Lett Drugs Ther. 2008 May 5;50(1285):33-4 | Show Full IntroductionHide Full Introduction

Budesonide/Formoterol (Symbicort) for Asthma

   
The Medical Letter on Drugs and Therapeutics • February 11, 2008;  (Issue 1279)
A combination of the corticosteroid budesonide and the long-acting beta2-agonist formoterol (Symbicort - AstraZeneca) has become available in a metered dose inhaler for long-term maintenance treatment of asthma...
A combination of the corticosteroid budesonide and the long-acting beta2-agonist formoterol (Symbicort - AstraZeneca) has become available in a metered dose inhaler for long-term maintenance treatment of asthma in patients ≥ 12 years old. A combination product that contains fluticasone propionate and salmeterol (Advair) is already available for this indication in the US. Neither one of these combinations is approved for acute treatment of asthma symptoms. A dry powder inhaler formulation of Symbicort has been available in Europe and Canada for several years.
Med Lett Drugs Ther. 2008 Feb 11;50(1279):9-11 | Show Full IntroductionHide Full Introduction

Fluticasone Furoate (Veramyst) for Allergic Rhinitis

   
The Medical Letter on Drugs and Therapeutics • November 5, 2007;  (Issue 1273)
Fluticasone furoate nasal spray (Veramyst - GSK) is now available for once-daily treatment of seasonal and perennial allergic rhinitis in adults and children ≥2 years old. It is similar to fluticasone...
Fluticasone furoate nasal spray (Veramyst - GSK) is now available for once-daily treatment of seasonal and perennial allergic rhinitis in adults and children ≥2 years old. It is similar to fluticasone propionate nasal spray (Flonase, and others), which is now available generically.
Med Lett Drugs Ther. 2007 Nov 5;49(1273):90-2 | Show Full IntroductionHide Full Introduction

Drugs for Allergic Disorders

   
The Medical Letter on Drugs and Therapeutics • August 1, 2007;  (Issue 60)
Allergic rhinitis, allergic conjunctivitis, atopic dermatitis, urticaria, anaphylaxis and asthma (reviewed in Treatment Guidelines 2005; 3:33 and not included here), are prevalent worldwide, especially in...
Allergic rhinitis, allergic conjunctivitis, atopic dermatitis, urticaria, anaphylaxis and asthma (reviewed in Treatment Guidelines 2005; 3:33 and not included here), are prevalent worldwide, especially in industrialized countries. Pharmacologic treatment of these disorders continues to improve in efficacy and safety. In addition to using drugs to prevent and control the symptoms of their allergic diseases, patients should also be instructed to avoid, if possible, specific allergens and/or environmental conditions that trigger or worsen their symptoms.
Treat Guidel Med Lett. 2007 Aug;5(60):71-80 | Show Full IntroductionHide Full Introduction

Mometasone (Asmanex Twisthaler) for Asthma

   
The Medical Letter on Drugs and Therapeutics • December 5, 2005;  (Issue 1223)
The FDA has approved marketing of the corticosteroid mometasone furoate in an orally inhaled dry powder formulation (Asmanex Twisthaler - Schering-Plough) for maintenance treatment of asthma in patients at...
The FDA has approved marketing of the corticosteroid mometasone furoate in an orally inhaled dry powder formulation (Asmanex Twisthaler - Schering-Plough) for maintenance treatment of asthma in patients at least 12 years old. Mometasone is also available as a mid-potency topical corticosteroid cream (Elocon) and as an intranasal spray (Nasonex) for treatment of allergic rhinitis.
Med Lett Drugs Ther. 2005 Dec 5;47(1223):98-9 | Show Full IntroductionHide Full Introduction

Montelukast (Singulair) for Perennial Allergic Rhinitis

   
The Medical Letter on Drugs and Therapeutics • October 24, 2005;  (Issue 1220)
Montelukast (Singulair - Merck) is an oral cysteinyl leukotriene D4 receptor antagonist originally marketed for treatment of asthma. It was approved by the FDA in 2003 for treatment of seasonal allergic...
Montelukast (Singulair - Merck) is an oral cysteinyl leukotriene D4 receptor antagonist originally marketed for treatment of asthma. It was approved by the FDA in 2003 for treatment of seasonal allergic rhinitis and recently for use in perennial allergic rhinitis in adults and children ≥ 6 months old. Intranasal corticosteroids have generally been considered the most effective drugs available for prevention and treatment of allergic rhinitis.
Med Lett Drugs Ther. 2005 Oct 24;47(1220):87-4 | Show Full IntroductionHide Full Introduction

Drugs for Acne, Rosacea and Psoriasis

   
The Medical Letter on Drugs and Therapeutics • July 1, 2005;  (Issue 35)
The pathogenesis of acne is multifactorial: follicular hyperkeratinization, Propionibacterium acnes bacteria, sebum production, androgens and inflammation have all been implicated. P. acnes, a gram-positive...
The pathogenesis of acne is multifactorial: follicular hyperkeratinization, Propionibacterium acnes bacteria, sebum production, androgens and inflammation have all been implicated. P. acnes, a gram-positive microaerophilic bacterium, plays an important role in the development of acne lesions by secreting chemotactic factors that attract leukocytes to the follicle, causing inflammation.
Treat Guidel Med Lett. 2005 Jul;3(35):49-56 | Show Full IntroductionHide Full Introduction

Drugs for Allergic Disorders

   
The Medical Letter on Drugs and Therapeutics • November 1, 2003;  (Issue 15)
Allergic rhinitis, allergic conjunctivitis, atopic dermatitis, urticaria and anaphylaxis, along with asthma (reviewed in Treatment Guidelines 2002; 1:7 and not included here), have increased in prevalence...
Allergic rhinitis, allergic conjunctivitis, atopic dermatitis, urticaria and anaphylaxis, along with asthma (reviewed in Treatment Guidelines 2002; 1:7 and not included here), have increased in prevalence during the past 30 years and are now epidemic worldwide, especially in industrialized countries. Many safe and effective drugs are currently available for prevention and relief of symptoms in these disorders, but pharmacological treatment alone may not be sufficient. Patients should also be instructed to avoid specific allergens or environmental conditions that trigger their symptoms. Allergen-specific immunotherapy, parenteral administration of gradually increasing doses of the allergen ("allergy shots"), has been effective in allergic rhinitis, allergic conjunctivitis and allergic asthma, and also in prevention of anaphylaxis triggered by stings from bees, yellow jackets, hornets and wasps. It has not been effective in food allergy, atopic dermatitis or urticaria.
Treat Guidel Med Lett. 2003 Nov;1(15):93-100 | Show Full IntroductionHide Full Introduction

Montelukast (Singulair) for Allergic Rhinitis

   
The Medical Letter on Drugs and Therapeutics • March 17, 2003;  (Issue 1152)
Montelukast (Singulair - Merck), a leukotriene receptor antagonist already marketed for asthma (Treatment Guidelines from The Medical Letter 2002; 1:11), has been approved by the FDA for treatment of seasonal...
Montelukast (Singulair - Merck), a leukotriene receptor antagonist already marketed for asthma (Treatment Guidelines from The Medical Letter 2002; 1:11), has been approved by the FDA for treatment of seasonal allergic rhinitis in adults and children more than 2 years old.
Med Lett Drugs Ther. 2003 Mar 17;45(1152):21-2 | Show Full IntroductionHide Full Introduction

Fluticasone Propionate Nasal Spray for Allergic Rhinitis

   
The Medical Letter on Drugs and Therapeutics • January 20, 1995;  (Issue 940)
An intranasal spray formulation of the corticosteroid fluticasone propionate (floo tik a sone; Flonase - Allen & Hanburys) has been approved by the US Food and Drug Administration for treatment of seasonal...
An intranasal spray formulation of the corticosteroid fluticasone propionate (floo tik a sone; Flonase - Allen & Hanburys) has been approved by the US Food and Drug Administration for treatment of seasonal and perennial allergic rhinitis in adults and children more than 12 years old.
Med Lett Drugs Ther. 1995 Jan 20;37(940):5-6 | Show Full IntroductionHide Full Introduction

Topical Corticosteroids

   
The Medical Letter on Drugs and Therapeutics • November 15, 1991;  (Issue 857)
Two new topical corticosteroids - fluticasone (Cutivate - Glaxo), a mediumpotency product, and halobetasol propionate (Ultravate - Westwood-Squibb), a superhigh- potency drug- were recently approved for...
Two new topical corticosteroids - fluticasone (Cutivate - Glaxo), a mediumpotency product, and halobetasol propionate (Ultravate - Westwood-Squibb), a superhigh- potency drug- were recently approved for marketing by the US Food and Drug Administration.
Med Lett Drugs Ther. 1991 Nov 15;33(857):108-10 | Show Full IntroductionHide Full Introduction